A recent survey by KFF reveals that approximately one out of every eight adults in the United States has used Ozempic or another GLP-1 medication




According to fresh survey data from KFF, roughly one in eight adults in the United States have utilized a GLP-1 medication such as Ozempic or Mounjaro. Presently, around half of this group, which accounts for approximately 6% of all adults, totaling more than 15 million individuals, are actively prescribed these drugs.

Over the past year, the US Food and Drug Administration has noted shortages of GLP-1 medications like Ozempic, Wegovy, and Mounjaro across various dosage levels due to soaring demand, prompting drug manufacturers to scramble to meet supply needs. Novo Nordisk recently disclosed that at least 25,000 individuals in the US are initiating its medication Wegovy each week, a fivefold increase compared to December's weekly intake.
According to recent survey data, the majority of adults who have utilized these medications have done so to manage chronic ailments such as diabetes or heart disease. Over 40% of respondents with diabetes and roughly a quarter of those with heart disease reported using 

GLP-1 drugs.
However, approximately 40% of adults have used GLP-1 drugs solely for weight loss, as revealed by the KFF poll. Despite neither Ozempic nor Mounjaro being explicitly approved for weight loss, the FDA sanctioned them for treating type 2 diabetes in 2017 and 2022, respectively. Nevertheless, doctors frequently prescribe them off-label for weight management. Wegovy, authorized in 2021 for obesity treatment, contains semaglutide, the same primary ingredient as Ozempic, while Mounjaro employs a slightly different one called tirzepatide.

Overall, adults aged 50 to 64 were the most frequent users of GLP-1 drugs, although younger adults were more inclined to utilize them solely for weight loss, according to findings from the KFF survey.